Loading...
Market
What percentage of HIV prevention market will Lenacapavir capture by end of 2025?
2
Resolution / Starting Odds
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Market analysis reports from healthcare and pharmaceutical industry analysts
Story
Twice-Yearly Lenacapavir Injection Shows 95% Effectiveness, 96% Risk Reduction in HIV Prevention
Dec 1, 2024, 01:35 PM
A twice-yearly injectable HIV prophylactic, Lenacapavir, has shown over 95% effectiveness in preventing HIV infections in men, according to recent studies. The injection has also been proven effective in women and offers a significant advantage over daily pills like F/TDF due to better adherence rates. Another study highlighted that a semi-annual injection reduced the risk of HIV infection by 96%. Additionally, achieving an undetectable viral load through consistent antiretroviral therapy means zero risk of transmission. This development represents a promising step toward combating HIV/AIDS, although questions remain about equitable access to the treatment.
View original story
Similar markets
Below 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
Above 30% • 25%
Less than 10% • 25%
10%-30% • 25%
31%-50% • 25%
More than 50% • 25%
Less than 25% • 25%
25% to 50% • 25%
50% to 75% • 25%
More than 75% • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
Less than 25% • 25%
25% to 50% • 25%
50% to 75% • 25%
More than 75% • 25%
Less than 10 • 25%
10 to 20 • 25%
21 to 30 • 25%
More than 30 • 25%
Less than 50% • 25%
50% to 75% • 25%
76% to 99% • 25%
100% or more • 25%
Fewer than 10 countries • 25%
10 to 20 countries • 25%
21 to 30 countries • 25%
More than 30 countries • 25%
0-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Reduction by less than 5% • 25%
Reduction by 5% to 10% • 25%
Reduction by 10% to 15% • 25%
Reduction by more than 15% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%